XTRA:EVTLife Sciences
Is Evotec (XTRA:EVT) Cheap After Cutting Its 2026 Revenue Guidance?
Evotec (XTRA:EVT) cut its full year 2026 revenue guidance to a range of €570 million to €610 million after issuing preliminary first half figures, with investors now watching the upcoming Q2 earnings call for clarity.
See our latest analysis for Evotec.
The lowered 2026 guidance appears to have weighed heavily on sentiment, with Evotec’s share price down 30.62% over the past week and its 1 year total shareholder return falling 53.29%. This extends already weak multi year performance and...